A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer

Clinical Snapshot

Key Findings

• P Value: Not reported for efficacy endpoints

• Effect Size: 0% objective response rate (0/29 evaluable patients)

• Primary Outcome: Safety and tolerability established across eight dose cohorts with myelosuppression as primary toxicity

• Nnt Or Sensitivity: Stable disease rate: 21% (6/29 patients), with 10% (3/29) achieving stable disease >4 months

• Confidence Interval: Not provided for efficacy outcomes

Clinical Application

Limited by significant myelosuppression requiring careful monitoring. Oral agents provide convenience but toxicity profile concerning Would require TGA approval for combination use. PBS listing unlikely given lack of efficacy. May inform future combination strategies in Australian cancer centres Heavily pretreated patients with TNBC or hormone-resistant breast cancer without BRCA mutations, similar to Australian advanced breast cancer population

Abstract

BACKGROUND: Poly(adenosine diphosphate ribose) polymerase (PARP) is recruited to DNA damage sites along with epigenetic factors such as DNA methyltransferase 1 (DNMT1). Inhibitors of DNMT modulate reactive oxygen species (ROS)-cyclic adenosine monophosphate (cAMP)/Protein Kinase A signaling and induce a "BRCAness phenotype" that further sensitizes cells to PARPi. In preclinical studies, combined DNMTi + PARPi therapy was effective in both triple-negative (TNBC) and hormone resistant (HRBC) models with intact BRCA. METHODS: The authors conducted a phase 1 study combining the oral DNMTi ASTX727 with the PARPi talazoparib in patients with previously treated TNBC or HRBC. Patients with deleterious mutations of BRCA were excluded. A classical 3+3 design guided dose escalation/de-escalation, and 28 days constituted each cycle. Serial peripheral blood mononuclear cells (PBMCs) were analyzed for changes in methylation using the Infinium Methylation EPIC BeadChip and LINE1 sequencing. RESULTS: Thirty-four evaluable patients were enrolled and treated in eight dose cohorts. Myelosuppression was common with grade >3 neutropenia in 42% and grade 3 anemia and thrombocytopenia in 13%. Dose-limiting toxicity was limited to neutropenia. Efficacy was assessed in 29 patients. There were no objective responses, six patients had stable disease persisting for >4 months in three patients. LINE1 demethylation ranged from ∼2%-10% and immune-specific CpGs (methylation in immune cells) changed 1%-5% at day 15. Methylation changes were not dose-dependent. CONCLUSIONS: ASTX727 plus talazoparib produces significant myelosuppression without other adverse events. Modest methylation changes in PBMCs were detected. There were no objective responses, but some heavily pretreated patients had stable disease for >4 months despite the attenuated doses.

References

1. 1.Miller, K. D., Thomas, A., Althouse, S., Zang, Y., Conder, E., Burgos, R., Schneider, B. P., Ballinger, T., Douglas, E., Ansley, K., Jang, H. J., Chung, W., Issa, J. P., Nephew, K. P., & Rassool, F. V. (2026). A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer. Cancer. https://doi.org/10.1002/cncr.70407